Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
McKinsey
Harvard Business School
Johnson and Johnson
McKesson

Last Updated: December 7, 2019

DrugPatentWatch Database Preview

Litigation Details for Galderma Laboratories LP v. Actavis Laboratories UT Inc. (D. Del. 2015)

See Plans and Pricing

« Back to Dashboard

Galderma Laboratories LP v. Actavis Laboratories UT Inc. (D. Del. 2015)

Docket   Start Trial Date Filed 2015-03-12
Court District Court, D. Delaware Date Terminated 2017-01-05
Cause 35:271 Patent Infringement Assigned To Leonard Philip Stark
Jury Demand None Referred To
Parties ACTAVIS LABORATORIES UT INC.; GALDERMA LABORATORIES LP; NESTLE SKIN HEALTH S.A.; NOVUM PHARMACEUTICAL RESEARCH SERVICES
Patents 7,439,241; 8,053,427; 8,163,725; 8,231,885; 8,410,102; 8,426,410; 8,513,247; 8,513,249; 8,859,551
Attorneys Evan D. Diamond; Jack B. Blumenfeld; James L. Higgins; Jennifer P. Nock; Maryellen Noreika; Melanie K. Sharp; Robert M. Vrana; Vanessa Y. Yen
Link to Docket External link to docket
Small Molecule Drugs cited in Galderma Laboratories LP v. Actavis Laboratories UT Inc.
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for Galderma Laboratories LP v. Actavis Laboratories UT Inc. (D. Del. 2015)

Date Filed Document No. Description Snippet Link To Document
2016-06-30 135 alleging infringement of U .S . Patent Nos. 7,439,241 1 (the '" 241 patent"), 8,410,1022 (the …"'249 patent") (collectively, "patents-in-suit"). The patents-in-suit claim compounds… '241 patent is invalid for obviousness type double patenting over the '410 patent, which Plaintiffs…the '" 102 patent"), 8,426,410 3 ("the "'410 patent"), 8,859,551 4 (the…the "' 551 patent"), 8,513 ,247 5 (the '" 247 patent"), and 8,513,249 6 (the External link to document
2016-09-15 182 Regarding Actavis's Infringement of U.S. Patent Nos. 7,439,241, 8,426,410, 8,513,247, and 8,513,249 filed…2015 5 January 2017 1:15-cv-00232-LPS Patent None District Court, D. Delaware External link to document
2016-10-24 186 ., Ph.D. Regarding the Validity of U.S. Patent Nos. 7,439,241, 8,426,410, 8,513,247, and 8,513, 249; and…2015 5 January 2017 1:15-cv-00232-LPS Patent None District Court, D. Delaware External link to document
2016-11-15 194 Regarding Actavis's Infringement of U.S. Patent Nos. 7,439,241, 8,426,410, 8,513,247, and 8,513,249 filed…2015 5 January 2017 1:15-cv-00232-LPS Patent None District Court, D. Delaware External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Dow
Harvard Business School
Medtronic
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.